Consensus NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-04 pm EST			5-day change	1st Jan Change
29.23 ^USD	-4.20%		+48.45%	+95.78%

Dec. 02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
Dec. 02	NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint	MT

Evolution of the Average Target: NovoCure Limited

average-target-price-chart NOVOCURE-LIMITED

Evolution of the Target Price: NovoCure Limited

target-price-consensus-chart NOVOCURE-LIMITED

Changes in Analyst Recommendations: NovoCure Limited

9c7e58ad.xwxgQ-OAgi3JujRxO629whRme0CXtuJ7f_Td0sOg4CE.8UYzJLGttWyo6H4rDNr7kG1eSCzS9JsRCcKQp7H2plKzdSwZ0drlWo7XeQ~974db7981f05a63b2e72f99be89f2b53

Analysts' recommendations: NovoCure Limited

HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	Dec. 02	MT
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating	Dec. 02	MT
Evercore ISI Upgrades NovoCure to Outperform	Dec. 02	MT
HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24	Oct. 16	MT
Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	Jun. 04	MT
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	Apr. 10	MT
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	Apr. 03	MT
Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	Feb. 23	MT
Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	23-10-26	MT
Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	23-08-29	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	23-08-28	MT
HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	23-08-28	MT
Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	23-08-28	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	23-08-28	MT
Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	23-08-08	MT
SVB Securities Initiates NovoCure at Outperform With $51 Price Target	23-08-04	MT
Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	23-07-31	MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	23-06-07	MT
Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	23-06-07	MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	23-06-07	MT
Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $104 From $70	23-05-16	MT
Wedbush Cuts NovoCure's Price Target to $53 From $65 After Lower-Than-Expected Q1 Results, Keeps Underperform Rating	23-05-05	MT
JPMorgan Downgrades NovoCure to Underweight From Neutral, Adjusts Price Target to $50 From $99	23-03-17	MT
Piper Sandler Adjusts NovoCure's Price Target to $80 From $70, Maintains Neutral Rating	23-01-17	MT
JPMorgan Adjusts NovoCure's Price Target to $99 From $86, Keeps Neutral Rating	23-01-06	MT

More recommendations

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
NOVOCURE LIMITED			+3.48%
PENUMBRA, INC.			-1.70%
MASIMO CORPORATION			-2.97%
APT MEDICAL INC.			+5.50%
ASAHI INTECC CO., LTD.			+25.03%
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.			+34.86%
GETINGE AB			+30.47%
INARI MEDICAL, INC.			+22.81%
SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD	-	-	-
Average			+14.68%
Weighted average by Cap.			+10.87%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

30.51USD

Average target price

31.57USD

Spread / Average Target

+3.48%

High Price Target

40.00USD

Spread / Highest target

+31.10%

Low Price Target

19.00USD

Spread / Lowest Target

-37.73%

Analyst Consensus Detail

Consensus revision (last 18 months)

consensus-revision-chart NOVOCURE-LIMITED

Analysts covering the company

HC Wainwright
Leerink Partners
Evercore ISI
Wedbush
Piper Sandler
Wells Fargo Securities
SVB Securities LLC
JPMorgan Chase
Truist Securities
Loop Capital
Oppenheimer
Mizuho Securities
Northland Securities
J.P. Morgan Chase